



**PRESS RELEASE**

September 23,  
2021  
Gothenburg

## Language correction: XVIVO Capital Markets Day presents strategic focus areas for 2022-2026

**By mistake the english press release went out in Swedish. Below is the press release in english.**

**At the XVIVO Capital Markets Day in Gothenburg, Sweden today, CEO Dag Andersson and other senior executives will focus on the company's strategy to become the world leader in the transplant industry.**

XVIVO will present five strategic focus areas for the period 2022 – 2026; Global leader Abdominal (with initial focus on the US); Market leading heart preservation system; Increase penetration of machine perfusion; Secure all-inclusive reimbursement in key geographic areas; and China to become the company's second largest market.

*"Strategy is about making choices and about deliberately choosing to be different, and always for us considering our overall vision that nobody should die waiting for a new organ. With our five strategic focus areas we have defined our way forward and the keys to our future success"* says Dag Andersson, CEO.

During the Capital Markets Day, financial targets and the actions to reach these targets will be presented. XVIVO's ambition is to reach an EBIT-margin of 20 % and an EBITDA-margin of 30 % during the strategy period. In 2026, Abdominal revenue is expected to be of equal size as Thoracic revenue.

XVIVO will continue to build on its world leading position in lung transplantation and develop the offering to cover all four major organs: lung, heart, kidney and liver.

The Capital Markets Day will be broadcasted live online today, on 23 September 2021, at 13:00 CEST via this link: <https://xvivo.creo.se/210923>. A recording of the Capital Markets Day will be available on-demand shortly after the event via the same link.

### **For further information, please contact:**

---

Kristoffer Nordström, CFO and IR, +46 73 519 21 64, e-mail: [kristoffer.nordstrom@xvivogroup.com](mailto:kristoffer.nordstrom@xvivogroup.com)  
Anne Lycke, Executive Assistant, +46 735 192 146, e-mail: [anne.lycke@xvivogroup.com](mailto:anne.lycke@xvivogroup.com)

## About Us

---

Founded in 1998, XVIVO is the only medical technology company dedicated to extending the life of all major organs - so transplant teams around the world can save more lives. Our solutions allow leading clinicians and researchers to push the boundaries of transplantation medicine. XVIVO is headquartered in Gothenburg, Sweden, and has offices and research sites on two continents. The company is listed on Nasdaq and has the ticker symbol XVIVO. More information can be found on the website [www.xvivogroup.com](http://www.xvivogroup.com).

*This information is information that XVIVO Perfusion AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact persons set out above, at 2021-09-23 09:13 CEST.*

## Attachments

---

**Language correction: XVIVO Capital Markets Day presents strategic focus areas for 2022-2026**